Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Astellas, Roche Diabetes Care Japan reach partnership agreement » 20:04
03/28/23
03/28
20:04
03/28/23
20:04
ALPMY

Astellas Pharma

$14.44 /

+0.25 (+1.76%)

, RHHBY

Roche

$34.88 /

-0.22 (-0.63%)

Astellas Pharma (ALPMY)…

Astellas Pharma (ALPMY) announced that it has entered into an agreement with Roche Diabetes Care Japan Co., Ltd. (RHHBY) for the development and commercialization of Roche Diabetes Care's world-renowned Accu-Chek Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar. BlueStar is an FDA-cleared digital health solution for diabetes patients, developed by Welldoc, Inc. and is currently marketed in the U.S. and Canada. Astellas and Welldoc are jointly developing BlueStar in Japan. In the future, Astellas will aim to obtain regulatory approval and reimbursement as a combined medical product.

ShowHide Related Items >><<
RHHBY Roche
$34.88 /

-0.22 (-0.63%)

ALPMY Astellas Pharma
$14.44 /

+0.25 (+1.76%)

ALPMY Astellas Pharma
$14.44 /

+0.25 (+1.76%)

03/07/23 Jefferies
Astellas Pharma price target raised to 2,300 yen from 2,200 yen at Jefferies
11/10/22 BTIG
Taysha Gene Therapies price target lowered to $15 from $25 at BTIG
11/09/22 Truist
Taysha cash overhang removed after Astellas investment, says Truist
10/26/22 Truist
Taysha Gene Therapies price target lowered to $15 from $35 at Truist
RHHBY Roche
$34.88 /

-0.22 (-0.63%)

03/27/23 Barclays
Roche downgraded to Equal Weight from Overweight at Barclays
03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
02/27/23 Societe Generale
Societe Generale upgrades Roche to Buy, says 'enough is enough'
02/27/23 Societe Generale
Roche upgraded to Buy from Hold at Societe Generale
RHHBY Roche
$34.88 /

-0.22 (-0.63%)

RHHBY Roche
$34.88 /

-0.22 (-0.63%)

RHHBY Roche
$34.88 /

-0.22 (-0.63%)

Recommendations
Viking Therapeutics price target raised to $31 from $20 at BTIG » 13:07
03/28/23
03/28
13:07
03/28/23
13:07
VKTX

Viking Therapeutics

$14.79 /

+5.66 (+61.99%)

, LLY

Eli Lilly

$335.88 /

+1.47 (+0.44%)

, NVO

Novo Nordisk

$155.25 /

+0.59 (+0.38%)

BTIG raised the…

BTIG raised the firm's price target on Viking Therapeutics (VKTX) to $31 from $20 and keeps a Buy rating on the shares. The firm is impressed by the attractive early clinical profile of VK2735 with significant weight loss after just 28-days of treatment with good tolerability, and views the positive data release as a de-risking event for the asset, with an initial clinical profile that is strongly competitive to Eli Lilly's (LLY) Mounjaro and appears more efficacious than Novo's (NVO) semaglutide, the analyst tells investors in a research note.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$14.79 /

+5.66 (+61.99%)

NVO Novo Nordisk
$155.25 /

+0.59 (+0.38%)

LLY Eli Lilly
$335.88 /

+1.47 (+0.44%)

VKTX Viking Therapeutics
$14.79 /

+5.66 (+61.99%)

03/28/23 Oppenheimer
Viking Therapeutics price target raised to $30 from $20 at Oppenheimer
03/28/23 Stifel
Stifel reiterates Buy on Viking Therapeutics, raises price target to $25
03/28/23 H.C. Wainwright
Viking's VK2735 looks like 'heavyweight contender,' says H.C. Wainwright
03/22/23 Stifel
Stifel argues sympathy trading not a predictor for Viking's pending VK2735 data
LLY Eli Lilly
$335.88 /

+1.47 (+0.44%)

03/17/23 Stifel
Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class'
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
NVO Novo Nordisk
$155.25 /

+0.59 (+0.38%)

03/09/23 JPMorgan
Novo Nordisk price target raised to DKK 1,200 from DKK 1,100 at JPMorgan
03/02/23 Morgan Stanley
Novo Nordisk named 'Catalyst Driven Idea' at Morgan Stanley
01/26/23 Citi
Novartis downgraded to Neutral from Buy at Citi
01/18/23 Deutsche Bank
Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
VKTX Viking Therapeutics
$14.79 /

+5.66 (+61.99%)

NVO Novo Nordisk
$155.25 /

+0.59 (+0.38%)

LLY Eli Lilly
$335.88 /

+1.47 (+0.44%)

VKTX Viking Therapeutics
$14.79 /

+5.66 (+61.99%)

LLY Eli Lilly
$335.88 /

+1.47 (+0.44%)

VKTX Viking Therapeutics
$14.79 /

+5.66 (+61.99%)

NVO Novo Nordisk
$155.25 /

+0.59 (+0.38%)

LLY Eli Lilly
$335.88 /

+1.47 (+0.44%)

VKTX Viking Therapeutics
$14.79 /

+5.66 (+61.99%)

NVO Novo Nordisk
$155.25 /

+0.59 (+0.38%)

LLY Eli Lilly
$335.88 /

+1.47 (+0.44%)

Monday
Conference/Events
Oppenheimer emerging biotech analyst to hold analyst/industry conference call » 13:25
03/27/23
03/27
13:25
03/27/23
13:25
RLAY

Relay Therapeutics

$15.62 /

+0.29 (+1.89%)

, ARVN

Arvinas

$26.77 /

+0.37 (+1.40%)

, OLMA

Olema Oncology

$3.64 /

+0.1 (+2.82%)

, AMAM

Ambrx Biopharma

$9.18 /

-0.15 (-1.61%)

, GILD

Gilead

$80.14 /

+0.12 (+0.15%)

, AZN

AstraZeneca

$68.93 /

+1.01 (+1.49%)

, LLY

Eli Lilly

$334.19 /

-1.865 (-0.55%)

Biotechnology Analyst…

Biotechnology Analyst Biegler, along with Dr. Christos Vaklavas discuss the HR+ metastatic breast cancer landscape, expectations for upcoming initial data for RLY-2608 (PI3Kalpha), unmet need for oral SERD(s), and the impact of Enhertu on the HR+ space (relevant companies RLAY, ARVN, OLMA, AMAM, GILD, AZN, LLY) on an Analyst/Industry conference call to be held on March 27 at 2 pm.

ShowHide Related Items >><<
OLMA Olema Oncology
$3.64 /

+0.1 (+2.82%)

LLY Eli Lilly
$334.19 /

-1.865 (-0.55%)

GILD Gilead
$80.14 /

+0.12 (+0.15%)

AZN AstraZeneca
$68.93 /

+1.01 (+1.49%)

ARVN Arvinas
$26.77 /

+0.37 (+1.40%)

AMAM Ambrx Biopharma
$9.18 /

-0.15 (-1.61%)

RLAY Relay Therapeutics
$15.62 /

+0.29 (+1.89%)

03/09/23 Guggenheim
Relay Therapeutics price target lowered to $28 from $45 at Guggenheim
03/07/23 H.C. Wainwright
Relay Therapeutics price target raised to $46 from $43 at H.C. Wainwright
02/02/23 Oppenheimer
Relay Therapeutics initiated with an Outperform at Oppenheimer
01/19/23 JMP Securities
Relay Therapeutics price target lowered to $28 from $38 at JMP Securities
ARVN Arvinas
$26.77 /

+0.37 (+1.40%)

03/18/23 Citi
Arvinas price target raised to $77 from $72 at Citi
02/23/23 Capital One
Arvinas remains one of the best biotechs to own, says Capital One
01/17/23 Truist
Arvinas price target lowered to $65 from $100 at Truist
01/12/23 Capital One
Arvinas pullback a buying opportunity, says Capital One
OLMA Olema Oncology
$3.64 /

+0.1 (+2.82%)

03/10/23 H.C. Wainwright
Olema Oncology price target raised to $15 from $12 at H.C. Wainwright
02/22/23 Credit Suisse
Olema Oncology initiated with an Outperform at Credit Suisse
07/06/22 Canaccord
Olema Oncology assumed with a Buy at Canaccord
06/09/22 H.C. Wainwright
H.C. Wainwright upgrades Olema to Buy after 'huge positive' in data
AMAM Ambrx Biopharma
$9.18 /

-0.15 (-1.61%)

03/03/23 Baird
Ambrx Biopharma price target raised to $11 from $4 at Baird
10/19/22 Baird
Ambrx Biopharma price target lowered to $4 from $8 at Baird
09/21/22 Baird
Ambrx Biopharma price target lowered to $8 from $16 at Baird
04/07/22 Baird
Baird starts Ambrx Biopharma with Outperform, $16 price target
GILD Gilead
$80.14 /

+0.12 (+0.15%)

03/20/23 Oppenheimer
Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news
03/13/23 Stifel
Arcellx initiated with a Buy at Stifel
02/14/23 Mizuho
Gilead price target raised to $101 from $88 at Mizuho
02/10/23 TD Cowen
Gilead price target raised to $95 from $90 at Cowen
AZN AstraZeneca
$68.93 /

+1.01 (+1.49%)

03/15/23 Berenberg
AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg
03/07/23 Guggenheim
Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs
03/07/23 Evercore ISI
Mineralys Therapeutics initiated with an Outperform at Evercore ISI
02/21/23 UBS
AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS
LLY Eli Lilly
$334.19 /

-1.865 (-0.55%)

03/22/23 Stifel
Stifel argues sympathy trading not a predictor for Viking's pending VK2735 data
03/17/23 Stifel
Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class'
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
RLAY Relay Therapeutics
$15.62 /

+0.29 (+1.89%)

OLMA Olema Oncology
$3.64 /

+0.1 (+2.82%)

LLY Eli Lilly
$334.19 /

-1.865 (-0.55%)

GILD Gilead
$80.14 /

+0.12 (+0.15%)

AZN AstraZeneca
$68.93 /

+1.01 (+1.49%)

ARVN Arvinas
$26.77 /

+0.37 (+1.40%)

  • 13
    Sep
LLY Eli Lilly
$334.19 /

-1.865 (-0.55%)

AZN AstraZeneca
$68.93 /

+1.01 (+1.49%)

RLAY Relay Therapeutics
$15.62 /

+0.29 (+1.89%)

OLMA Olema Oncology
$3.64 /

+0.1 (+2.82%)

LLY Eli Lilly
$334.19 /

-1.865 (-0.55%)

GILD Gilead
$80.14 /

+0.12 (+0.15%)

AZN AstraZeneca
$68.93 /

+1.01 (+1.49%)

ARVN Arvinas
$26.77 /

+0.37 (+1.40%)

LLY Eli Lilly
$334.19 /

-1.865 (-0.55%)

GILD Gilead
$80.14 /

+0.12 (+0.15%)

AZN AstraZeneca
$68.93 /

+1.01 (+1.49%)

AMAM Ambrx Biopharma
$9.18 /

-0.15 (-1.61%)

Hot Stocks
BioNTech sees FY23 Covid-19 vaccine revenue ~EUR 5B » 06:49
03/27/23
03/27
06:49
03/27/23
06:49
BNTX

BioNTech

$128.00 /

-1.28 (-0.99%)

, PFE

Pfizer

$40.39 /

+0.22 (+0.55%)

This revenue estimate…

This revenue estimate reflects expected revenues related to BioNTech's (BNTX) share of gross profit from COVID-19 vaccine sales in the collaboration partner's territories, from direct COVID-19 vaccine sales to customers in BioNTech's territory and expected revenues from sales to collaboration partners which may be influenced by costs like inventory write-offs once materialized and shared with the collaboration partner Pfizer (PFE).

ShowHide Related Items >><<
PFE Pfizer
$40.39 /

+0.22 (+0.55%)

BNTX BioNTech
$128.00 /

-1.28 (-0.99%)

BNTX BioNTech
$128.00 /

-1.28 (-0.99%)

03/23/23 H.C. Wainwright
BioNTech price target lowered to $210 from $272 at H.C. Wainwright
12/15/22 BofA
BioNTech upgraded to Buy at BofA oncology pipeline opportunities
12/15/22 BofA
BioNTech upgraded to Buy from Neutral at BofA
11/08/22 Canaccord
BioNTech price target lowered to $191 from $200 at Canaccord
PFE Pfizer
$40.39 /

+0.22 (+0.55%)

03/24/23 Berenberg
Seagen downgraded to Hold from Buy at Berenberg
03/21/23 TD Cowen
Seagen price target raised to $229 from $145 at TD Cowen
03/20/23 Truist
Seagen price target raised to $229 from $152 at Truist
03/17/23 Wells Fargo
Pfizer price target lowered to $44 from $50 at Wells Fargo
PFE Pfizer
$40.39 /

+0.22 (+0.55%)

BNTX BioNTech
$128.00 /

-1.28 (-0.99%)

PFE Pfizer
$40.39 /

+0.22 (+0.55%)

BNTX BioNTech
$128.00 /

-1.28 (-0.99%)

PFE Pfizer
$40.39 /

+0.22 (+0.55%)

BNTX BioNTech
$128.00 /

-1.28 (-0.99%)

PFE Pfizer
$40.39 /

+0.22 (+0.55%)

Hot Stocks
Ionis Pharmaceuticals announces NEURO-TTRansform study met co-primary endpoints » 05:18
03/27/23
03/27
05:18
03/27/23
05:18
IONS

Ionis Pharmaceuticals

$33.96 /

+0.31 (+0.92%)

, AZN

AstraZeneca

$67.92 /

+0.66 (+0.98%)

Ionis Pharmaceuticals…

Ionis Pharmaceuticals (IONS) announced topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's (AZN) eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy, or ATTRv-PN, a debilitating and potentially fatal disease that leads to peripheral nerve damage and motor disability. At 66 weeks, patients treated with eplontersen continued to demonstrate a statistically significant and clinically meaningful change from baseline versus an external placebo group on the co-primary endpoints of modified Neuropathy Impairment Score +7, a measure of neuropathic disease progression, and Norfolk Quality of Life Questionnaire-Diabetic Neuropathy. The study also met its third co-primary endpoint demonstrating a statistically significant reduction in serum TTR concentration versus an external placebo group. TTR reductions were consistent with those reported at week 35. Eplontersen continued to demonstrate a safety and tolerability profile consistent with that observed at 35 weeks. Data from both the 35 and 66-week analyses will be presented as an Emerging Science presentation at the American Academy of Neurology annual meeting in April. The initial results from the 35-week analysis were presented at the International Symposium on Amyloidosis meeting in September 2022. As part of a global development and commercialization agreement, Ionis and AstraZeneca are seeking regulatory approval for eplontersen for the treatment of ATTRv-PN in the U.S. and plan to seek regulatory approval in Europe and other parts of the world. Earlier this month, the FDA accepted a new drug application for eplontersen for the treatment of ATTRv-PN with a PDUFA action date of Dec. 22, 2023. Eplontersen was granted orphan drug designation in the U.S.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$33.96 /

+0.31 (+0.92%)

AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

IONS Ionis Pharmaceuticals
$33.96 /

+0.31 (+0.92%)

03/21/23 Bernstein
Ionis Pharmaceuticals initiated with an Underperform at Bernstein
02/23/23 SVB Securities
Ionis Pharmaceuticals price target lowered to $27 from $34 at SVB Securities
02/23/23 Barclays
Ionis Pharmaceuticals price target lowered to $40 from $44 at Barclays
01/19/23 Piper Sandler
Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler
AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

03/15/23 Berenberg
AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg
03/07/23 Guggenheim
Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs
03/07/23 Evercore ISI
Mineralys Therapeutics initiated with an Outperform at Evercore ISI
02/21/23 UBS
AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS
IONS Ionis Pharmaceuticals
$33.96 /

+0.31 (+0.92%)

AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

IONS Ionis Pharmaceuticals
$33.96 /

+0.31 (+0.92%)

AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

Conference/Events
Oppenheimer emerging biotech analyst to hold analyst/industry conference call » 04:55
03/27/23
03/27
04:55
03/27/23
04:55
RLAY

Relay Therapeutics

$15.33 /

-0.12 (-0.78%)

, ARVN

Arvinas

$26.46 /

+0.185 (+0.70%)

, OLMA

Olema Oncology

$3.60 /

+0.1 (+2.86%)

, AMAM

Ambrx Biopharma

$9.29 /

+0.64 (+7.40%)

, GILD

Gilead

$80.03 /

+1.23 (+1.56%)

, AZN

AstraZeneca

$67.92 /

+0.66 (+0.98%)

, LLY

Eli Lilly

$336.11 /

+3.5 (+1.05%)

Biotechnology Analyst…

Biotechnology Analyst Biegler, along with Dr. Christos Vaklavas discuss the HR+ metastatic breast cancer landscape, expectations for upcoming initial data for RLY-2608 (PI3Kalpha), unmet need for oral SERD(s), and the impact of Enhertu on the HR+ space (relevant companies RLAY, ARVN, OLMA, AMAM, GILD, AZN, LLY) on an Analyst/Industry conference call to be held on March 27 at 2 pm.

ShowHide Related Items >><<
OLMA Olema Oncology
$3.60 /

+0.1 (+2.86%)

LLY Eli Lilly
$336.11 /

+3.5 (+1.05%)

GILD Gilead
$80.03 /

+1.23 (+1.56%)

AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

ARVN Arvinas
$26.46 /

+0.185 (+0.70%)

AMAM Ambrx Biopharma
$9.29 /

+0.64 (+7.40%)

RLAY Relay Therapeutics
$15.33 /

-0.12 (-0.78%)

03/09/23 Guggenheim
Relay Therapeutics price target lowered to $28 from $45 at Guggenheim
03/07/23 H.C. Wainwright
Relay Therapeutics price target raised to $46 from $43 at H.C. Wainwright
02/02/23 Oppenheimer
Relay Therapeutics initiated with an Outperform at Oppenheimer
01/19/23 JMP Securities
Relay Therapeutics price target lowered to $28 from $38 at JMP Securities
ARVN Arvinas
$26.46 /

+0.185 (+0.70%)

03/18/23 Citi
Arvinas price target raised to $77 from $72 at Citi
02/23/23 Capital One
Arvinas remains one of the best biotechs to own, says Capital One
01/17/23 Truist
Arvinas price target lowered to $65 from $100 at Truist
01/12/23 Capital One
Arvinas pullback a buying opportunity, says Capital One
OLMA Olema Oncology
$3.60 /

+0.1 (+2.86%)

03/10/23 H.C. Wainwright
Olema Oncology price target raised to $15 from $12 at H.C. Wainwright
02/22/23 Credit Suisse
Olema Oncology initiated with an Outperform at Credit Suisse
07/06/22 Canaccord
Olema Oncology assumed with a Buy at Canaccord
06/09/22 H.C. Wainwright
H.C. Wainwright upgrades Olema to Buy after 'huge positive' in data
AMAM Ambrx Biopharma
$9.29 /

+0.64 (+7.40%)

03/03/23 Baird
Ambrx Biopharma price target raised to $11 from $4 at Baird
10/19/22 Baird
Ambrx Biopharma price target lowered to $4 from $8 at Baird
09/21/22 Baird
Ambrx Biopharma price target lowered to $8 from $16 at Baird
04/07/22 Baird
Baird starts Ambrx Biopharma with Outperform, $16 price target
GILD Gilead
$80.03 /

+1.23 (+1.56%)

03/20/23 Oppenheimer
Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news
03/13/23 Stifel
Arcellx initiated with a Buy at Stifel
02/14/23 Mizuho
Gilead price target raised to $101 from $88 at Mizuho
02/10/23 TD Cowen
Gilead price target raised to $95 from $90 at Cowen
AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

03/15/23 Berenberg
AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg
03/07/23 Guggenheim
Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs
03/07/23 Evercore ISI
Mineralys Therapeutics initiated with an Outperform at Evercore ISI
02/21/23 UBS
AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS
LLY Eli Lilly
$336.11 /

+3.5 (+1.05%)

03/22/23 Stifel
Stifel argues sympathy trading not a predictor for Viking's pending VK2735 data
03/17/23 Stifel
Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class'
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
RLAY Relay Therapeutics
$15.33 /

-0.12 (-0.78%)

OLMA Olema Oncology
$3.60 /

+0.1 (+2.86%)

LLY Eli Lilly
$336.11 /

+3.5 (+1.05%)

GILD Gilead
$80.03 /

+1.23 (+1.56%)

AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

ARVN Arvinas
$26.46 /

+0.185 (+0.70%)

  • 13
    Sep
LLY Eli Lilly
$336.11 /

+3.5 (+1.05%)

AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

RLAY Relay Therapeutics
$15.33 /

-0.12 (-0.78%)

OLMA Olema Oncology
$3.60 /

+0.1 (+2.86%)

LLY Eli Lilly
$336.11 /

+3.5 (+1.05%)

GILD Gilead
$80.03 /

+1.23 (+1.56%)

AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

ARVN Arvinas
$26.46 /

+0.185 (+0.70%)

LLY Eli Lilly
$336.11 /

+3.5 (+1.05%)

GILD Gilead
$80.03 /

+1.23 (+1.56%)

AZN AstraZeneca
$67.92 /

+0.66 (+0.98%)

AMAM Ambrx Biopharma
$9.29 /

+0.64 (+7.40%)

Downgrade
Roche downgraded to Equal Weight from Overweight at Barclays » 04:31
03/27/23
03/27
04:31
03/27/23
04:31
RHHBY

Roche

$35.37 /

+0.35 (+1.00%)

Barclays downgraded Roche…

Barclays downgraded Roche to Equal Weight from Overweight with a price target of CHF 270, down from CHF 350. Roche remains in a "transitional" period, and believe investors want to see more out of the pipeline before sentiment will improve, the analyst tells investors in a research note. "In this market, defense wins championships," writes the firm.

ShowHide Related Items >><<
RHHBY Roche
$35.37 /

+0.35 (+1.00%)

RHHBY Roche
$35.37 /

+0.35 (+1.00%)

03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
02/27/23 Societe Generale
Societe Generale upgrades Roche to Buy, says 'enough is enough'
02/27/23 Societe Generale
Roche upgraded to Buy from Hold at Societe Generale
02/15/23 JMP Securities
iBio downgraded to Market Perform at JMP on CDMO and IBIO-101 questions
RHHBY Roche
$35.37 /

+0.35 (+1.00%)

RHHBY Roche
$35.37 /

+0.35 (+1.00%)

RHHBY Roche
$35.37 /

+0.35 (+1.00%)

Friday
Downgrade
Seagen downgraded to Hold from Buy at Berenberg » 06:38
03/24/23
03/24
06:38
03/24/23
06:38
SGEN

Seagen

$198.06 /

-0.59 (-0.30%)

, PFE

Pfizer

$40.17 /

+0.175 (+0.44%)

Berenberg analyst…

Berenberg analyst Zhiqiang Shu downgraded Seagen (SGEN) to Hold from Buy with a price target of $229, up from $170. The analyst cites the pending takeover by Pfizer (PFE) for $229 per share in cash for the downgrade. The companies expect the deal to close in late 2023 or early 2024, contingent upon approval from regulators and Seagen shareholders, the analyst tells investors in a research note.

ShowHide Related Items >><<
SGEN Seagen
$198.06 /

-0.59 (-0.30%)

PFE Pfizer
$40.17 /

+0.175 (+0.44%)

SGEN Seagen
$198.06 /

-0.59 (-0.30%)

03/21/23 TD Cowen
Seagen price target raised to $229 from $145 at TD Cowen
03/20/23 Truist
Seagen price target raised to $229 from $152 at Truist
03/15/23 Morgan Stanley
Seagen downgraded to Equal Weight from Overweight at Morgan Stanley
03/14/23 RBC Capital
Seagen price target raised to $229 from $155 at RBC Capital
PFE Pfizer
$40.17 /

+0.175 (+0.44%)

03/17/23 Wells Fargo
Pfizer price target lowered to $44 from $50 at Wells Fargo
SGEN Seagen
$198.06 /

-0.59 (-0.30%)

PFE Pfizer
$40.17 /

+0.175 (+0.44%)

SGEN Seagen
$198.06 /

-0.59 (-0.30%)

PFE Pfizer
$40.17 /

+0.175 (+0.44%)

SGEN Seagen
$198.06 /

-0.59 (-0.30%)

PFE Pfizer
$40.17 /

+0.175 (+0.44%)

PFE Pfizer
$40.17 /

+0.175 (+0.44%)

Thursday
Hot Stocks
AstraZeneca says Calquence conditionally approved in China for first indication » 06:50
03/23/23
03/23
06:50
03/23/23
06:50
AZN

AstraZeneca

$66.55 /

-0.425 (-0.63%)

AstraZeneca's…

AstraZeneca's Calquence, a next generation, selective Bruton's tyrosine kinase inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma, or MCL, who have received at least one prior therapy, the company announced. "This is the first approved indication for Calquence in China," AstraZeneca stated.

ShowHide Related Items >><<
AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

03/15/23 Berenberg
AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg
03/07/23 Guggenheim
Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs
03/07/23 Evercore ISI
Mineralys Therapeutics initiated with an Outperform at Evercore ISI
02/21/23 UBS
AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS
AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

Over a week ago
Conference/Events
Oppenheimer emerging biotech analyst to hold analyst/industry conference call » 16:40
03/22/23
03/22
16:40
03/22/23
16:40
RLAY

Relay Therapeutics

$15.21 /

-0.3401 (-2.19%)

, ARVN

Arvinas

$27.65 /

-1.485 (-5.10%)

, OLMA

Olema Oncology

$3.43 /

-0.235 (-6.41%)

, AMAM

Ambrx Biopharma

$9.09 /

-0.96 (-9.55%)

, GILD

Gilead

$77.77 /

-1.38 (-1.74%)

, AZN

AstraZeneca

$66.55 /

-0.425 (-0.63%)

, LLY

Eli Lilly

$331.02 /

+0.015 (+0.00%)

Biotechnology Analyst…

Biotechnology Analyst Biegler, along with Dr. Christos Vaklavas discuss the HR+ metastatic breast cancer landscape, expectations for upcoming initial data for RLY-2608 (PI3Kalpha), unmet need for oral SERD(s), and the impact of Enhertu on the HR+ space (relevant companies RLAY, ARVN, OLMA, AMAM, GILD, AZN, LLY) on an Analyst/Industry conference call to be held on March 27 at 2 pm.

ShowHide Related Items >><<
OLMA Olema Oncology
$3.43 /

-0.235 (-6.41%)

LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

GILD Gilead
$77.77 /

-1.38 (-1.74%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

ARVN Arvinas
$27.65 /

-1.485 (-5.10%)

AMAM Ambrx Biopharma
$9.09 /

-0.96 (-9.55%)

RLAY Relay Therapeutics
$15.21 /

-0.3401 (-2.19%)

03/09/23 Guggenheim
Relay Therapeutics price target lowered to $28 from $45 at Guggenheim
03/07/23 H.C. Wainwright
Relay Therapeutics price target raised to $46 from $43 at H.C. Wainwright
02/02/23 Oppenheimer
Relay Therapeutics initiated with an Outperform at Oppenheimer
01/19/23 JMP Securities
Relay Therapeutics price target lowered to $28 from $38 at JMP Securities
ARVN Arvinas
$27.65 /

-1.485 (-5.10%)

03/18/23 Citi
Arvinas price target raised to $77 from $72 at Citi
02/23/23 Capital One
Arvinas remains one of the best biotechs to own, says Capital One
01/17/23 Truist
Arvinas price target lowered to $65 from $100 at Truist
01/12/23 Capital One
Arvinas pullback a buying opportunity, says Capital One
OLMA Olema Oncology
$3.43 /

-0.235 (-6.41%)

03/10/23 H.C. Wainwright
Olema Oncology price target raised to $15 from $12 at H.C. Wainwright
02/22/23 Credit Suisse
Olema Oncology initiated with an Outperform at Credit Suisse
07/06/22 Canaccord
Olema Oncology assumed with a Buy at Canaccord
06/09/22 H.C. Wainwright
H.C. Wainwright upgrades Olema to Buy after 'huge positive' in data
AMAM Ambrx Biopharma
$9.09 /

-0.96 (-9.55%)

03/03/23 Baird
Ambrx Biopharma price target raised to $11 from $4 at Baird
10/19/22 Baird
Ambrx Biopharma price target lowered to $4 from $8 at Baird
09/21/22 Baird
Ambrx Biopharma price target lowered to $8 from $16 at Baird
04/07/22 Baird
Baird starts Ambrx Biopharma with Outperform, $16 price target
GILD Gilead
$77.77 /

-1.38 (-1.74%)

03/20/23 Oppenheimer
Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news
03/13/23 Stifel
Arcellx initiated with a Buy at Stifel
02/14/23 Mizuho
Gilead price target raised to $101 from $88 at Mizuho
02/10/23 TD Cowen
Gilead price target raised to $95 from $90 at Cowen
AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

03/15/23 Berenberg
AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg
03/07/23 Guggenheim
Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs
03/07/23 Evercore ISI
Mineralys Therapeutics initiated with an Outperform at Evercore ISI
02/21/23 UBS
AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS
LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

03/22/23 Stifel
Stifel argues sympathy trading not a predictor for Viking's pending VK2735 data
03/17/23 Stifel
Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class'
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
RLAY Relay Therapeutics
$15.21 /

-0.3401 (-2.19%)

OLMA Olema Oncology
$3.43 /

-0.235 (-6.41%)

LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

GILD Gilead
$77.77 /

-1.38 (-1.74%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

ARVN Arvinas
$27.65 /

-1.485 (-5.10%)

  • 13
    Sep
LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

RLAY Relay Therapeutics
$15.21 /

-0.3401 (-2.19%)

OLMA Olema Oncology
$3.43 /

-0.235 (-6.41%)

LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

GILD Gilead
$77.77 /

-1.38 (-1.74%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

ARVN Arvinas
$27.65 /

-1.485 (-5.10%)

LLY Eli Lilly
$331.02 /

+0.015 (+0.00%)

GILD Gilead
$77.77 /

-1.38 (-1.74%)

AZN AstraZeneca
$66.55 /

-0.425 (-0.63%)

AMAM Ambrx Biopharma
$9.09 /

-0.96 (-9.55%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.